Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Takeshita
Hideki
H
Kawakami
Satoru
S
Fukui
Iwao
I
D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000813:Anilides / Q000008:administration & dosage* / Q000009:adverse effects; D001707:Biopsy, Needle; D019008:Drug Resistance, Neoplasm; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009367:Neoplasm Staging; D009570:Nitriles / Q000008:administration & dosage* / Q000009:adverse effects; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D020266:Radiotherapy, Conformal; D018570:Risk Assessment; D016879:Salvage Therapy; D013375:Substance Withdrawal Syndrome / Q000209:etiology* / Q000503:physiopathology; D014105:Tosyl Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D017430:Prostate-Specific Antigen